Abstract: The present disclosure concerns methods and compositions related to adoptive cell therapy and its efficacy related to the gut microbiome. In specific cases, it may be determined for an individual whether or not a chimeric antigen receptor (CAR) T-cell therapy will be effective for an individual based on their gut microbiome. An individual may be provided a composition comprising one or more particular microbe compositions based on analysis of the gut microbiome of the individual and prior to administration of CAR T-cell therapy, in specific embodiments.

Abstract: The present disclosure provides ?2?-1 C-terminal domain mimetics for the treatment of pain, epilepsy or other disorders in a subject. Further provided is an ?2?-1 C-terminal domain peptide which blocks binding of ?2?-1 to the glutamate receptors NMDAR and AMPAR.

Abstract: The current disclosure describes effective therapeutic treatments and diagnostic/prognostic methods for colorectal cancer based on the expression or activity level of biomarkers. Aspects of the disclosure relate to a method for treating a subject for colorectal cancer, the method comprising treating the subject for colorectal cancer after the expression level of one or more biomarker genes from Table 1, Table 2, Table 3, Table 4, Table 5, Table S2, Table S3, Table S4, Table S5, FIG. 4A, and/or FIG. 4B has been determined in a sample from the subject.

Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.

Abstract: The invention provides for novel glaucoma surgical devices comprising a microfluidic meshwork. The meshwork comprises interconnected, cellular-dimensioned microfluidic channels. Excess fluid in the eye can be drained and diffused through the microfluidic channels. The meshwork is porous and highly flexible, affording mechanical compliance similar to that of eye tissue. The meshwork minimizes foreign body reactions to the implant, decreasing fibrosis and capsule formation.

Abstract: Methods and systems for screening therapeutic compositions for the treatment of age-related macular degeneration (AMD) or for the prevention of progression of AMD, wherein retinal pigment epithelium cells (RPE) are cultured and the level of hypoxia-induced exosome release from the RPE cells is subsequently measured. In the present invention, the level of hypoxia-induced exosome release can be correlated with AMD onset and severity.

Abstract: Assessing a thermal conductivity of a viscoelastic material in a steady state using a conduction method includes i) allowing a sample of the viscoelastic material to reach thermal equilibrium in a liquid at a first temperature, ii) assessing a heat flow of the sample at the first temperature, iii) repeating i) and ii) at one or more additional temperatures, and iv) assessing the thermal conductivity of the viscoelastic material based on the heat flow of the sample at the first temperature and the one or more additional temperatures, a cross-sectional area of the sample, and a temperature-thickness gradient of the sample at thermal equilibrium.

Abstract: Various embodiments of a system and associated method for generating a valid mapping for a computational loop on a CGRA are disclosed herein. In particular, the method includes generating randomized schedules within particular constraints to explore greater mapping spaces than previous approaches. Further, the system and related method employs a feasibility test to test validity of each schedule such that mappings are only generated from valid schedules.

Abstract: Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes.

Abstract: A phosphorescent emitter or delayed fluorescent and phosphorescent emitters represented by Formula I or Formula II, where M is platinum or palladium.

Abstract: The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide. eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.

Abstract: Various embodiments of a system and methods for audio source separation via multi-scale feature learning are disclosed.

Abstract: A two-step thermochemical reactor and method are disclosed. The reactor includes a housing and a reactor cavity formed within, and surrounded by, thermal insulation within the housing. The reactor cavity includes at least one unit cell, each cell having an electric heat source and a reactive material. The reactor also includes a feedstock inlet and a product outlet in fluid communication with the reactor cavity. The reactor also includes a reducing configuration, with the inlet being closed and the electric heat source of each unit cell being driven to thermally reduce the reactive material at a first temperature, releasing oxygen into the cavity. The reactor also has a splitting configuration where the reactive material is at a second temperature that is lower than the first, the feedstock inlet open and introducing feedstock gas into the cavity to reoxidize the reactive material and split into a product gas.

Abstract: A system for failure detection tools is disclosed. The system may include at least one user device, an application server, and a failure detection system, each of which may be in communication with one or more of the others via at least one network. The failure detection system may receive first data from a data source, process the first data to generate second data, apply a statistical modeling algorithm to make a prediction relating to the first data or the second data, and communicate data relating to the prediction and/or a trend related to the first data or the second data to the user device for displaying at least a portion of the data relating to the prediction and/or the trend on a display of the user device.

Abstract: A light emitting device includes a transparent organic light emitting device and a quarter-wave plate. The transparent organic light emitting device includes a chiral complex emitter and produces circularly polarized light, and the quarter-wave plate converts the circularly polarized light into linearly polarized light. Generating linearly polarized light includes generating circularly polarized light via a transparent organic light emitting device including a chiral complex emitter, and passing the circularly polarized light through a quarter-wave plate to yield linearly polarized light.

Abstract: The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.

Abstract: A safety-guaranteed control system for automated vehicles (AVs) considers both vehicle and tire stabilities on varying road conditions. Conventional AV control systems may not be sufficient to adequately handle control-dependent and time-varying safety constraints. The system integrates control-dependent barrier functions (CDBF) and time-varying CBFs (TCBFs) with control Lyapunov functions (CLFs) in a quadratic programming problem.

Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

Abstract: Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.

Abstract: The disclosure provides a flexible, narrow medical device (such as a micro-catheter or a guidewire) that is controllably moved and steered through lumens of a body. The medical device may include an electrically-actuatable bendable portion at a distal end, which may be provided by a polymer electrolyte layer, electrodes distributed about the polymer electrolyte layer, and electrical conduits coupled to the electrodes, such that the polymer electrolyte layer deforms asymmetrically in response to an electrical signal through one or more conduits. The disclosure further includes a controller for moving the device into and out of bodily lumens and for applying the electrical signal for steering the device. The device further includes methods of preparing the polymer electrolyte layer in tubular shape.